EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses -mutated breast cancer.

To investigate the role of EF2K in -mutated breast cancer. We developed silica coated cobalt-ferrite (CoFe) nanoparticles for  delivery of small interfering RNAs (siRNAs) into -mutated breast cancer. Expression of EF2K is highly upregulated in the majority (78.5%) of -mutated patients and significantly associated with poor patient survival and metastasis. Silencing of EF2K reduced cell proliferation, migration and invasion of the cancer cells. therapeutic targeting of EF2K by CoFe-siRNA-nanoparticles leads to sustained gene knockdown and suppressed tumor growth in orthotopic xenograft models of BRCA1-mutated breast cancer. EF2K is a potential novel molecular target in -mutated tumors and CoFe-based siRNA nanotherapy may be used as a novel approach to target EF2K.